Teclistamab

Generic Name
Teclistamab
Brand Names
Tecvayli
Drug Type
Biotech
Chemical Formula
-
CAS Number
2119595-80-9
Unique Ingredient Identifier
54534MX6Z9
Background

Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells. Teclistamab consists of an anti-BCMA arm and an anti-CD3 arm connected via two interchain disulfide bonds, allowing the drug to recruit CD3-expressing T cells to B...

Indication

Teclistamab is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
...

Associated Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Associated Therapies
-
Clinical Trials
Related News
koreabiomed.com
·

[ASH 2024] J&J targets curing half of multiple myeloma patients with innovative treatment portfolio

Johnson & Johnson aims to cure half of all multiple myeloma patients, shifting from disease management to potential cure. Their therapies, including Darzalex and Carvykti, have shown significant improvements in progression-free survival and response rates, with innovative approaches like bispecific antibodies and precision medicine. The company emphasizes early use of effective treatments to reduce healthcare burden.
cancernetwork.com
·

Maintenance Teclistamab Yields Preliminary Activity in NDMM

All evaluable patients in the MajesTEC-4/EMN30 trial achieved MRD negativity with teclistamab-cqyv maintenance after ASCT for NDMM, with deepening responses and manageable hematologic toxicity. The trial includes Tec-Len and Tec monotherapy cohorts, with varying dosing schedules. The study is now moving into its main randomization phase, aiming to enroll 1500 patients.
stocktitan.net
·

J&J's TECVAYLI® Achieves Breakthrough 100% Response Rate in Multiple Myeloma Clinical Trials

Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data showing 100% MRD negativity in newly diagnosed multiple myeloma patients treated with MajesTEC-5 induction and MajesTEC-4 maintenance therapies, presented at the 2024 ASH Annual Meeting.

Related Clinical Trials:

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
prnewswire.com
·

TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for ...

Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data from MajesTEC-5 and MajesTEC-4 studies, showing 100% MRD negativity in evaluable patients with newly diagnosed multiple myeloma, presented at the 2024 ASH Annual Meeting.

Related Clinical Trials:

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
onclive.com
·

Dr Dhakal on Notable Multiple Myeloma Trials Presented in 2024

Key trials at the 21st International Myeloma Society Annual Meeting, including CEPHEUS and AURIGA, showcased promising data on daratumumab combinations, CAR T-cell therapies, and bispecific antibodies, highlighting advancements in multiple myeloma treatment.

Related Clinical Trials:

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy